NYSE:ZTS

Zoetis Stock Forecast, Price & News

$186.44

+2.33 (+1.27 %)

(As of 06/17/2021 12:00 AM ET)

Add

Compare

Today's Range

$183.78

▼

$186.93

50-Day Range

$159.85

▼

$186.44

52-Week Range

$131.28

▼

$186.93

Volume1.25 million shs

Average Volume1.94 million shs

Market Capitalization$88.52 billion

P/E Ratio50.25

Dividend Yield0.54%

Beta0.65

30 days | 90 days | 365 days | Advanced Chart

Receive ZTS News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

About Zoetis

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; Dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Hedge Funds Cashing Out Of Zoetis Inc (ZTS) - Yahoo Finance
June 17, 2021 | finance.yahoo.com

Hedge Funds Cashing Out Of Zoetis Inc (ZTS)
June 17, 2021 | finance.yahoo.com

Elanco Strikes Deal to Better Compete With Rival Zoetis in Pet Dermatology - Barron's
June 16, 2021 | barrons.com

Zoetis (NYSE:ZTS) Hits New 1-Year High at $186.74
June 16, 2021 | americanbankingnews.com

Zoetis A.L.P.H.A. Initiative Improves Livestock Health and Farmers’ Livelihoods in Sub-Saharan Africa with 1.7 billion Doses of Vaccines and Medicines administered in Four Years - Yahoo Finance
June 10, 2021 | finance.yahoo.com

Zoetis (NYSE:ZTS) Reaches New 52-Week High at $178.93
June 10, 2021 | americanbankingnews.com

Zoetis Inc.'s (NYSE:ZTS) Business Is Trailing The Market But Its Shares Aren't - Nasdaq
June 4, 2021 | nasdaq.com

Zoetis Adds Devices for Use in Regenerative Medicine Therapies to its Growing Equine Portfolio - Yahoo Finance
June 3, 2021 | finance.yahoo.com

Zoetis Releases 2020 Sustainability Report and Creates the Zoetis Foundation, Marking Progress in Creating a Healthier Future for Communities, Animals and the Planet - Business Wire
June 3, 2021 | businesswire.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNYSE:ZTS
Previous Symbol
CUSIP98978V10
CIK1555280
Webwww.zoetis.com
Phone973-822-7000
Employees11,300
Year Founded2012

Sales & Book Value

Annual Sales$6.68 billion
Price / Sales13.26
Cash Flow$4.92 per share
Price / Cash Flow37.90
Book Value$7.94 per share
Price / Book23.48

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares474,767,000
Market Cap$88.52 billion
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

Social Links

MarketRank^™

Overall MarketRank^™

1.81 out of 5 stars

Medical Sector

195th out of 2,100 stocks

Pharmaceutical Preparations Industry

87th out of 831 stocks

1.3 Analyst's Opinion

Consensus Rating
Zoetis has received a consensus rating of Buy. The company's average rating score is 2.54, and is based on 7 buy ratings, 6 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $184.25, Zoetis has a forecasted downside of 1.2% from its current price of $186.44.
Amount of Analyst Coverage
Zoetis has only been the subject of 4 research reports in the past 90 days.

3.2 Community Rank

Outperform Votes
Zoetis has received 843 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Zoetis has received 488 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Zoetis has received 63.34% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote “Outperform” if you believe ZTS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.

1.7 Dividend Strength

Dividend Yield
Zoetis has a dividend yield of 0.54%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Zoetis has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of Zoetis is 25.97%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Zoetis will have a dividend payout ratio of 19.92% next year. This indicates that Zoetis will be able to sustain or increase its dividend.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zoetis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,319,012.00 in company stock.
Percentage Held by Insiders
Only 0.17% of the stock of Zoetis is held by insiders.
Percentage Held by Institutions
90.21% of the stock of Zoetis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Zoetis are expected to grow by 11.56% in the coming year, from $4.50 to $5.02 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zoetis is 50.25, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.09.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zoetis is 50.25, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 44.10.
Price to Earnings Growth Ratio
Zoetis has a PEG Ratio of 3.15. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Zoetis has a P/B Ratio of 23.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Zoetis (NYSE:ZTS) Frequently Asked Questions

Is Zoetis a buy right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 6 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zoetis stock.
View analyst ratings for Zoetis or view top-rated stocks.

What stocks does MarketBeat like better than Zoetis?

Wall Street analysts have given Zoetis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zoetis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Zoetis' next earnings date?

Zoetis is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Zoetis.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) posted its quarterly earnings results on Thursday, May, 6th. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.04 by $0.22. The business had revenue of $1.87 billion for the quarter, compared to analysts' expectations of $1.73 billion. Zoetis had a net margin of 25.30% and a trailing twelve-month return on equity of 55.11%. The firm's revenue for the quarter was up 22.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.95 EPS.
View Zoetis' earnings history.

How has Zoetis' stock been impacted by Coronavirus?

Zoetis' stock was trading at $130.27 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ZTS stock has increased by 43.1% and is now trading at $186.44.
View which stocks have been most impacted by COVID-19.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis declared a quarterly dividend on Thursday, May 20th. Stockholders of record on Wednesday, July 21st will be paid a dividend of $0.25 per share on Wednesday, September 1st. This represents a $1.00 dividend on an annualized basis and a yield of 0.54%. The ex-dividend date of this dividend is Tuesday, July 20th.
View Zoetis' dividend history.

Is Zoetis a good dividend stock?

Zoetis pays an annual dividend of $1.00 per share and currently has a dividend yield of 0.54%. Zoetis does not yet have a strong track record of dividend growth. The dividend payout ratio of Zoetis is 25.97%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Zoetis will have a dividend payout ratio of 19.92% next year. This indicates that Zoetis will be able to sustain or increase its dividend.
View Zoetis' dividend history.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis updated its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share (EPS) guidance of 4.420-4.510 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.450. The company issued revenue guidance of $7.50 billion-$7.63 billion, compared to the consensus revenue estimate of $7.47 billion.

What price target have analysts set for ZTS?

13 brokers have issued 1 year price objectives for Zoetis' shares. Their forecasts range from $160.00 to $208.00. On average, they expect Zoetis' share price to reach $184.25 in the next twelve months. This suggests that the stock has a possible downside of 1.2%.
View analysts' price targets for Zoetis or view top-rated stocks among Wall Street analysts.

Who are Zoetis' key executives?

Zoetis' management team includes the following people:

Ms. Kristin C. Peck, CEO & Director (Age 50, Pay $2.79M) (LinkedIn Profile)
Mr. Glenn C. David, Group Pres & Exec. VP (Age 49, Pay $1.53M) (LinkedIn Profile)
Ms. Wafaa Mamilli, Exec. VP and Chief Information & Digital Officer (Age 54, Pay $2.6M) (LinkedIn Profile)
Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 60, Pay $1.51M) (LinkedIn Profile)
Mr. Roman Trawicki, Exec. VP and Pres of Global Manufacturing & Supply (Age 57, Pay $2.19M) (LinkedIn Profile)
Mr. Wetteny N. Joseph, Exec. VP & CFO (Age 49)
Ms. Roxanne Lagano, Exec. VP and Chief HR Officer & Global Operations (Age 56) (LinkedIn Profile)
Mr. Steven Frank, VP of Investor Relations
Ms. Heidi C. Chen, Exec. VP, Gen. Counsel & Corp. Sec. (Age 54) (LinkedIn Profile)
Mr. William Price, VP & Chief Communications Officer

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis CEO Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among Zoetis' employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

Who are some of Zoetis' key competitors?

Some companies that are related to Zoetis include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX), Supernus Pharmaceuticals (SUPN) and Endo International (ENDP).
View all of ZTS's competitors.

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Who are Zoetis' major shareholders?

Zoetis' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.31%), Alliancebernstein L.P. (3.75%), Polen Capital Management LLC (2.44%), Price T Rowe Associates Inc. MD (2.12%), Clearbridge Investments LLC (1.72%) and Geode Capital Management LLC (1.60%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Robert W Scully, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends for Zoetis.

Which major investors are selling Zoetis stock?

ZTS stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, BlackRock Inc., Jennison Associates LLC, Morgan Stanley, Amundi Asset Management US Inc., Massachusetts Financial Services Co. MA, The Manufacturers Life Insurance Company, and Cantillon Capital Management LLC. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Roxanne Lagano, and Willie M Reed.
View insider buying and selling activity for Zoetis or view top insider-selling stocks.

Which major investors are buying Zoetis stock?

ZTS stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Canada Pension Plan Investment Board, Arrowstreet Capital Limited Partnership, Price T Rowe Associates Inc. MD, Toronto Dominion Bank, Renaissance Technologies LLC, Principal Financial Group Inc., and UBS Asset Management Americas Inc..
View insider buying and selling activity for Zoetis or or view top insider-buying stocks.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $186.44.

How much money does Zoetis make?

Zoetis has a market capitalization of $88.52 billion and generates $6.68 billion in revenue each year. The company earns $1.64 billion in net income (profit) each year or $3.85 on an earnings per share basis.

How many employees does Zoetis have?

Zoetis employs 11,300 workers across the globe.

Does Zoetis have any subsidiaries?

The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Holding Limited, Abaxis Europe GmbH, Abaxis Holding GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma (Bermuda) LLC, Alpharma (Luxembourg) S.A.R.L. y Compania Limitada, Alpharma (Luxembourg) S.àr.l., Alpharma Animal Health (Hong Kong) Co. Limited, Alpharma Animal Health Company, Alpharma Euro Holdings LLC, Alpharma Holdings (Barbados) SRL, Alpharma LLC, Alpharma do Brasil Ltda., Bovigen, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Mikjan Corporation, NVIP Pty Ltd, Nexvet, Nexvet Australia Pty Ltd, Nordic Fish Tech AB, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PHARMAQ LTD, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS Technika SpA, Pharmaq Analytiq AS, Pharmaq CA Panama Inc., Pharmaq Fishteq AS, Pharmaq Holding AS, Pharmaq Settvac AS, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Platinum Performance, Platinum Performance Inc., Platinum Performance Nutrition Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics LLC, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis (Thailand) Limited, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark Aps, Zoetis Deutschland GmbH, Zoetis Egypt Import LLC, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management (Shanghai) Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis International Services, Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Lab Holdings LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa (Pty) Ltd., Zoetis Spain S.L., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Taiwan Limited, Zoetis Treasury Center BVBA, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..

When was Zoetis founded?

Zoetis was founded in 2012.

What is Zoetis' official website?

The official website for Zoetis is www.zoetis.com.

Where are Zoetis' headquarters?

Zoetis is headquartered at 10 Sylvan Way, Parsippany NJ, 07054.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]

This page was last updated on 6/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here